12:00 AM
 | 
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Vacc-4x: Preliminary Phase II data

Preliminary data from a single-blind, placebo-controlled, Norwegian Phase II trial in 24 HIV-infected patients who were stable on antiretroviral therapy (ART) showed that intranasal Vacc-4x plus Endocine adjuvant produced increased vaccine-related immune responses as measured by a DTH...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >